HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
AbstractSince the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-positive breast cancers. Currently, several HER2 directed antibody-drug conjugates are under clinical investigation for HER2 amplified but also HER2 expressing but not amplified breast tumors. In this article, we review the current preclinical and clinical evidence of the investigational drugs A166, ALT-P7, ARX788, DHES0815A, DS-8201a, RC48, SYD985, MEDI4276 and XMT-1522. View Full-Text
Share & Cite This Article
Rinnerthaler, G.; Gampenrieder, S.P.; Greil, R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int. J. Mol. Sci. 2019, 20, 1115.
Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. International Journal of Molecular Sciences. 2019; 20(5):1115.Chicago/Turabian Style
Rinnerthaler, Gabriel; Gampenrieder, Simon P.; Greil, Richard. 2019. "HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer." Int. J. Mol. Sci. 20, no. 5: 1115.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.